In strong agreement with our previous findings [24], PDGFRA-mutant GISTs are confirmed as the most immunogenic GIST molecular subgroup, showing a TIS score very similar to that of tumor types known to benefit from immunotherapy (such as lung cancer) (Figure 6). This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.